[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial

Authors:
Open Access
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • Novartis
  • Advanced Accelerator Applications

This publication has 26 references indexed in Scilit: